This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Non-small Cell Lung Cancer: Evidence Report
This report will form the basis of deliberation and discussion at the October 20, 2016 meeting of the Midwest CEPAC. A draft version of this report was open to public comment for four weeks and updated as necessary based on comments received.
This version includes a supplement that, based on newly available data, reviews evidence regarding population first-line use of PD-1 immunotherapy, and briefly discusses an additional trial regarding second-line use of PD-1 immunotherapy.View All Materials on this Topic or Go Back to View More Materials